Clinical Scorecard: Merck's investigational medication enlicitide significantly decreased cholesterol levels in a large-scale study

At a Glance

Key Highlights

• Enlicitide reduced LDL cholesterol by up to 60% over six months when added to standard statin therapy.
• The pill offers a non-injectable alternative to PCSK9 inhibitors with comparable LDL-lowering efficacy.
• No significant safety differences were observed between enlicitide and placebo over one year.

Guideline-Based Recommendations

Diagnosis

• Identify patients with high LDL cholesterol levels despite maximally tolerated statin therapy.
• Assess cardiovascular risk to determine LDL cholesterol targets (e.g., <70 mg/dL for high-risk patients).

Management

• Consider adding enlicitide to standard statin therapy for patients not achieving LDL goals.
• Administer enlicitide orally on an empty stomach to optimize absorption.

Monitoring & Follow-up

• Monitor LDL cholesterol levels periodically to assess treatment efficacy.
• Observe for any adverse effects during treatment, although none significant were reported in trials.

Risks

• Potential unknown long-term cardiovascular outcome benefits; ongoing studies are evaluating this.
• Adherence considerations due to requirement of taking enlicitide on an empty stomach.

Patient & Prescribing Data

High-risk patients with elevated LDL cholesterol despite statin therapy

Enlicitide provides a convenient oral alternative to injectable PCSK9 inhibitors with substantial LDL reduction and a favorable safety profile.

Clinical Best Practices

• Use enlicitide as an adjunct to statins in patients not achieving LDL cholesterol targets.
• Educate patients on the importance of taking enlicitide on an empty stomach for optimal effect.
• Continue to monitor lipid levels and cardiovascular risk factors regularly.
• Stay updated on emerging data regarding long-term cardiovascular outcomes with enlicitide.

References

• New England Journal of Medicine study on enlicitide
• FDA Fast Track Program